ErbB2 (HER-2) Monoclonal Antibody (CB11) | Invitrogen MA1-35720 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

ErbB2 (HER-2) Monoclonal Antibody (CB11)

catalog :

MA1-35720

quantity :

1 mL

price :

US 630

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

CB11

reactivity :

human, mouse, rat

application :

western blot, immunohistochemistry, immunocytochemistry, immunohistochemistry - paraffin section

citations: 40

Reference
Jeong J, Choi J, Kim W, Dann P, Takyar F, Gefter J, et al. Inhibition of ezrin causes PKCα-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells. J Biol Chem. 2019;294:887-901 pubmed publisher
Jeong J, Kim W, Kim L, VanHouten J, Wysolmerski J. HER2 signaling regulates HER2 localization and membrane retention. PLoS ONE. 2017;12:e0174849 pubmed publisher
Jeong J, VanHouten J, Kim W, Dann P, Sullivan C, Choi J, et al. The scaffolding protein NHERF1 regulates the stability and activity of the tyrosine kinase HER2. J Biol Chem. 2017;292:6555-6568 pubmed publisher
Soares M, Ribeiro R, Najmudin S, Gameiro A, Rodrigues R, Cardoso F, et al. Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status. Oncotarget. 2016;7:17314-26 pubmed publisher
Li H, Shen P, Liang Y, Zhang F. Fibroblastic reticular cell tumor of the breast: A case report and review of the literature. Exp Ther Med. 2016;11:561-564 pubmed
Jeong J, VanHouten J, Dann P, Kim W, Sullivan C, Yu H, et al. PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer. Proc Natl Acad Sci U S A. 2016;113:E282-90 pubmed publisher
Liu X, Feng C, Liu J, Zhao L, Liu J, Zhang W, et al. Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer. Tumour Biol. 2016;37:8027-36 pubmed publisher
Soares M, Correia J, Peleteiro M, Ferreira F. St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study. Tumour Biol. 2016;37:4053-64 pubmed publisher
Papanikolaou V, Stefanou N, Dubos S, Papathanasiou I, Palianopoulou M, Valiakou V, et al. Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes. Cell Oncol (Dordr). 2015;38:155-64 pubmed publisher
Li J, Zhang Y, Zhang W, Gao Y, Jia S, Guo J. Contrast enhanced computed tomography is indicative for angiogenesis pattern and display prognostic significance in breast cancer. BMC Cancer. 2014;14:672 pubmed publisher
Khandakar B, Mathur S, Kumar L, Kumar S, Datta Gupta S, Iyer V, et al. Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy. Biomed Res Int. 2014;2014:401245 pubmed publisher
Kim K, Lee K, Kim T, Chun Y, Lee T, Park H. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2014;17:40-6 pubmed publisher
Durgapal P, Mathur S, Kalamuddin M, Datta Gupta S, Parshad R, Julka P, et al. Assessment of Her-2/neu status using immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology smears: experience from a tertiary care centre in India. Diagn Cytopathol. 2014;42:726-31 pubmed publisher
Pracella D, Bonin S, Barbazza R, Sapino A, Castellano I, Sulfaro S, et al. Are breast cancer molecular classes predictive of survival in patients with long follow-up?. Dis Markers. 2013;35:595-605 pubmed publisher
Ren J, Jin F, Yu Z, Zhao L, Wang L, Bai X, et al. MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. Tumour Biol. 2013;34:3945-58 pubmed publisher
Zhang J, Wang Y, Yin Q, Zhang W, Zhang T, Niu Y. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy. Int J Clin Exp Pathol. 2013;6:1380-91 pubmed
Zhao Y, Li W, Lang R, Yang Y, Gao X, Zheng Y, et al. Primary acinic cell carcinoma of the breast: a case report and review of the literature. Int J Surg Pathol. 2014;22:177-81 pubmed publisher
Pereira C, Leal M, de Souza C, Montenegro R, Rey J, Carvalho A, et al. Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy. PLoS ONE. 2013;8:e60576 pubmed publisher
Lee G, Kim J, Koh E, Kang D, Choi D, Maeng K, et al. Plasma human mammaglobin mRNA associated with poor outcome in patients with breast cancer. Genet Mol Res. 2012;11:4034-42 pubmed publisher
Kim S, Jeong H, Woo O, Seo J, Kim A, Lee E, et al. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol. 2013;36:224-31 pubmed publisher
Jeong H, Ryu Y, An J, Lee Y, Kim A. Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology. 2012;60:E87-95 pubmed publisher
Bozkurt K, Kapucuoglu N. Investigation of immunohistochemical ER?, ER? and ER?cx expressions in normal and neoplastic breast tissues. Pathol Res Pract. 2012;208:133-9 pubmed publisher
Çiriş I, Bozkurt K, Baspinar S, Kapucuoğlu F. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study. Pathol Res Pract. 2011;207:182-7 pubmed publisher
Chen C, Xia H, Gong Y, Peng J, Peng C, Hu M, et al. The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis. Biomaterials. 2010;31:8818-25 pubmed publisher
Papanikolaou V, Iliopoulos D, Dimou I, Dubos S, Kappas C, Kitsiou Tzeli S, et al. Survivin regulation by HER2 through NF-?B and c-myc in irradiated breast cancer cells. J Cell Mol Med. 2011;15:1542-50 pubmed publisher
Delord J, Quideau S, Rochaix P, Caselles O, Couderc B, Hennebelle I, et al. Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model. Br J Cancer. 2010;103:61-72 pubmed publisher
Alberghini M, Kliskey K, Krenacs T, Picci P, Kindblom L, Forsyth R, et al. Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch. 2010;456:97-103 pubmed publisher
Kapucuoglu N, Percinel S, Ventura T, Lang R, Al Daraji W, Eusebi V. Dendritic cell sarcomas/tumours of the breast: report of two cases. Virchows Arch. 2009;454:333-9 pubmed publisher
Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol. 2008;39:167-74 pubmed
Rakesh Kumar V, Gupta N, Kakkar N, Sharma S. Prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma. J Cancer Res Ther. 2006;2:20-3 pubmed
Eroglu A, Sari A. Expression of c-kit proto-oncogene product in breast cancer tissues. Med Oncol. 2007;24:169-74 pubmed
Volante M, Saviozzi S, Rapa I, Ceppi P, Cappia S, Calogero R, et al. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer. Cancer. 2007;110:1321-8 pubmed
Oldford S, Robb J, Codner D, Gadag V, Watson P, Drover S. Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. Int Immunol. 2006;18:1591-602 pubmed
Delord J, Allal C, Canal M, Mery E, Rochaix P, Hennebelle I, et al. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Ann Oncol. 2005;16:1889-97 pubmed
Bodey B, Kaiser H, Siegel S. Epidermal growth factor receptor (EGFR) expression in childhood brain tumors. In Vivo. 2005;19:931-41 pubmed
Morandi L, Pession A, Marucci G, Foschini M, Pruneri G, Viale G, et al. Intraepidermal cells of Paget's carcinoma of the breast can be genetically different from those of the underlying carcinoma. Hum Pathol. 2003;34:1321-30 pubmed
Edgerton S, Moore D, Merkel D, Thor A. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol. 2003;11:214-21 pubmed
Ng W. Fine-needle aspiration cytology findings of an uncommon micropapillary variant of pure mucinous carcinoma of the breast: review of patients over an 8-year period. Cancer. 2002;96:280-8 pubmed
Marucci G, Betts C, Golouh R, Peterse J, Foschini M, Eusebi V. Toker cells are probably precursors of Paget cell carcinoma: a morphological and ultrastructural description. Virchows Arch. 2002;441:117-23 pubmed
Gilmour L, Macleod K, McCaig A, Gullick W, Smyth J, Langdon S. Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. Cancer Res. 2001;61:2169-76 pubmed

product information

Product Type :

Antibody

Product Name :

ErbB2 (HER-2) Monoclonal Antibody (CB11)

Catalog # :

MA1-35720

Quantity :

1 mL

Price :

US 630

Clonality :

Monoclonal

Host :

Mouse

Reactivity :

Human, Mammalia, Mouse, Rat

Applications :

Immunocytochemistry: 1:100, Immunofluorescence: 1:100, Immunohistochemistry (Paraffin): 1:40, Western Blot: 1:1000

Species :

Human, Mammalia, Mouse, Rat

Clone :

CB11

Isotype :

IgG1

Storage :

4° C

Description :

Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.

Immunogen :

Synthetic internal domain of the C-erbB-2 oncoprotein.

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 1:100, Immunofluorescence: 1:100, Immunohistochemistry (Paraffin): 1:40, Western Blot: 1:1000

Aliases :

avian erythroblastosis oncogene B 2; Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog); CD antigen CD340; CD340; c-erb B2/neu protein; c-erbB2; C-erbB-2; c-neu; epidermal growth factor receptor-related protein; erbb 2; ERBB2; erb-b2; Erbb-2; ErbB2 (pTyr1139); ErbB2 (pY1139); ErbB2 phospho Y1139; erb-b2 receptor tyrosine kinase 2; her 2; HER2; HER-2; HER-2/neu; herstatin; human epidermal growth factor receptor 2; Kiaa3023; metas; Metastatic lymph node gene 19 protein; mKIAA3023; MLN 19; MLN19; NEU; Neu oncogene; NEU proto-oncogene; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; NGL; p185erbB2; p185neu; phospho ErbB2; Proto-oncogene c-ErbB-2; proto-oncogene NEU; Receptor tyrosine-protein kinase erbB-2; TKR1; Tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)